Drugs / FusionVAC-22
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06789198 | Jul 2025 → Nov 2028 expected | fibrolamellar hepatocellular carcinoma | University Hospital Tuebingen | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FusionVAC-22 | “FusionVAC-22 peptide will be administered subcutaneously (s.c.) with the TLR1/2 ligand XS15 (50 µg) emulsified in Montanide ISA 51 VG (1:1).” NCT06789198 ↗ |
| Route | Subcutaneous | “FusionVAC-22 peptide will be administered subcutaneously (s.c.)” NCT06789198 ↗ |